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Abstract
Background
In people with multiple sclerosis treated with interferon-beta or glatiramer acetate, new MRI
lesions and relapses during the first year of treatment predict a poor prognosis.
Objective
To study this association in those receiving natalizumab.
Methods
Data were collected on relapses, new MRI activity, and Modified Rio Score after initiation of
natalizumab in an observational cohort of 161 patients with high baseline disability. These
were correlated with Expanded Disability Status Scale (EDSS) progression at years 1, 2, 3,
and 3–7 after treatment initiation, versus pre-treatment baseline.
Results
46/161 patients had a relapse in the first year and 44/161 had EDSS progression by year 2.
Relapses and Modified Rio Score in the first year of treatment predicted EDSS progression
at year 1 and 2 after treatment initiation. However, this effect disappeared with longer follow-
up. Paradoxically, there was a trend towards inflammatory activity on treatment (first year
Modified Rio Score, relapses, and MRI activity) predicting a lower risk of EDSS progression
by years 3–7, although this did not reach statistical significance. Those with and without
EDSS progression did not differ in baseline age, EDSS, or pre-treatment relapse rate.
Relapses in year 0–1 predicted further relapses in years 1–3.
Conclusions
Breakthrough inflammatory activity after natalizumab treatment is predictive of short-term
outcome measures of relapses or EDSS progression, but does not predict longer term
EDSS progression, in this cohort with high baseline disability.
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Introduction
In recent years, a number of new treatments have emerged for patients with relapsing multiple
sclerosis (RMS).[1] Their development was underpinned by targeting MRI activity in phase 2
studies, leading to phase 3 studies which demonstrated reductions in relapse frequency and a
variable effect on time to disability progression. The principal argument for their long term
use is that treatments that target inflammatory activity probably improve long term disability
outcomes, at least at a population level.[2, 3]
These principles have been extended in the pursuit of personalised medicine in multiple scle-
rosis (MS), where it is hypothesised that on-treatment breakthrough inflammatory activity can be
used to predict poor long-term disability outcomes at an individual level.[4] This is supported by
observational studies on therapies interferon-beta and glatiramer acetate, where early on-treat-
ment relapses, MRI activity, and Kurtzke Expanded Disability Status Scale (EDSS) disability pro-
gression have been shown to predict poor medium-term clinical outcomes of relapses and/or
EDSS progression in individuals.[5–11] For example, Rio and colleagues showed that combined
scores of MRI lesions, relapses, and/or EDSS progression after interferon-beta initiation predicted
further EDSS progression at two years.[9] Similarly, combined scores of MRI lesions and relapses
after glatiramer acetate predict “clinical activity” (defined as relapses or EDSS progression) after 2
years.[6] Most of these studies are limited in that their follow-up periods were between 2–3 years.
[6–11] Their applicability to other therapies such as teriflunomide, dimethyl fumarate, fingoli-
mod, natalizumab, and alemtuzumab is also uncertain. If on-treatment breakthrough inflamma-
tory activity does predict poor long-term disability outcomes, the next step would be to evaluate
whether switching treatments can improve long-term prognosis, as proposed by the no evidence
of disease activity (NEDA) approach.[12] However, for the treating physician, it is currently
unclear whether on-treatment inflammatory breakthrough activity should trigger a change in
medication, or not.
Natalizumab is a highly active therapy that is widely used in patients with RMS. It is effec-
tive in reducing relapses, MRI activity, and time to EDSS progression with a higher efficacy
than interferon-beta.[13, 14] The objective of this observational study was to evaluate whether
early relapses or MRI activity after starting natalizumab treatment predicts EDSS progression
at later time points, in a cohort with high baseline disability.
Patients and Methods
Data were collected from an observational cohort of 204 patients initiating natalizumab between
March 2007 and October 2010 at Imperial College Healthcare NHS Trust, with up to 7 years of
follow-up. Data on relapse rate and EDSS were prospectively documented at routine 6-monthly
clinic visits. EDSS data were collected until December 2014. MRI was routinely performed before
treatment and at one year. Data were retrospectively collated for the purpose of this study. Patients
were excluded if they had less than three years follow-up, or were treated with natalizumab for
less than one year.
Data were analysed as part of a clinical audit, registered and ethically approved at Imperial
College Healthcare NHS Trust, for which written informed consent was not required (Audit
registration number 1987–2015). Anonymised clinical data are not available on a public reposi-
tory since ethical approval was not granted by Imperial College Healthcare NHS Trust Research
Office to share individual patient disease characteristics outside of their healthcare institution,
since these may contain identifying or sensitive patient information. Requests for data may be
sent to richard.nicholas@imperial.nhs.uk.
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Early markers of inflammatory disease activity
Relapses were defined as an acute worsening of function lasting at least 48 hours, in the absence
of fever or infection. MRI activity was defined as the presence of 1 active lesion (either new or
enlarging T2 lesions) relative to a baseline MRI scan. A combined score of MRI and relapse activ-
ity was also applied to this first year after natalizumab therapy (Modified Rio Score–Table 1),
which employs more stringent criteria to define new MRI activity.[7]
Disease progression
Disability progression was defined as an increase of 1 EDSS point in those with EDSS <5.5, or
an increase of 0.5 EDSS point in those with EDSS5.5. EDSS progression was confirmed over
6 months at repeat clinic visits. Patients were labelled as disability progression responders and
non-responders after 1 year of treatment (Year 1 EDSS Progression) by comparing EDSS cap-
tured after 1 year with pre-natalizumab EDSS. This was repeated after 2 years, 3 years, and 3–7
years, by comparing the latest available EDSS rating (up to 7 years after treatment initiation)
with pre-natalizumab EDSS.
Statistical analysis
Demographic data are presented as mean +/- standard deviation (SD). Difference between
means was assessed using unpaired Student’s t-test, after testing for normality of the data. To
investigate the association between early markers of disease activity and disability progression
data were analysed in Kaplan-Meier curves using Log-Rank test and Cox regression, and also
in 2x2 contingency tables using Fisher’s exact test with odds ratios (OR) and 95% confidence
intervals (CI) calculated. Chi-squared test for trend was used for 3x2 contingency tables of the
Modified Rio Score and for analysis of change in categorical data over time. Corrections for
multiple comparisons were not made, since comparisons were complementary and a consis-
tency of results was apparent between different groups.[15, 16] For the purpose of displaying
results in graphical format, results were converted to percentages. A logical regression multi-
variable model was also used to investigate for multivariate associations that predict disability
outcomes. SPSS and R statistical package were used for these analyses.
Results
Demographics
During the study period, 204 patients started natalizumab treatment. Subjects were excluded
from analysis if they had discontinued natalizumab within 1 year (n = 16), if there were less
than 3 years of clinical follow-up data (n = 20), or if there were insufficient clinical or radiolog-
ical data (n = 7), leaving 161 patients for analysis. Of these, 127 received natalizumab
Table 1. Modified Rio Score[7].
Modified Rio Score scoring criteria
Criterion Change over 1st year Score
MRI  4 new T2 lesions 0
> 4 new T2 lesions 1
Relapse No relapses 0
1 relapse 1
 2 relapses 2
Score = MRI criterion + relapse criterion
doi:10.1371/journal.pone.0169546.t001
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throughout the study period, 9 stopped natalizumab after 1+ year of treatment and switched to
a new disease modifying medication, and 25 stopped natalizumab after 1+ year of treatment
but did not receive new disease modifying medication (Fig 1). No differences existed in demo-
graphic, clinical and MRI data between those included in and excluded from the study. There
were no differences between Year 3–7 EDSS Progression Responder and Year 3–7 EDSS Pro-
gression Non-Responder cohorts, other than an expected difference in most recent EDSS
(Table 2). Logistic regression multivariable analysis that included age, sex, disease duration,
number of previous treatments, pre-natalizumab relapse rate, and pre-natalizumab EDSS con-
firmed that none of these baseline measures predicted response to treatment.
Markers of inflammatory disease do not affect disability progression
survival analysis
46 of 161 patients had a relapse in the first year, and 28 of 161 had new MRI activity. Modified
Rio score was 1 in 34 patients, and 2 in 16 patients. Markers of inflammatory disease in the
first year (Modified Rio Score, relapses, MRI activity) and second year (relapses) had no signif-
icant effect on disability progression plotted as a survival analysis (Mod Rio Score year 0–1:
risk ratio (RR) 1.15, log-rank p = 0.74, Cox regression p = 0.44; Relapses year 0–1: RR 1.3, log-
rank p = 0.31, Cox regression p = 0.31; MRI activity year 0–1: RR 0.64, log-rank p = 0.21, Cox
regression p = 0.24; Relapses year 1–2: RR 1.17, log-rank p = 0.51, Cox regression p = 0.51;
Fig 1. 161 participants were included in all analyses. The treatment pathway, and mean follow-up time, is
detailed in the figure.
doi:10.1371/journal.pone.0169546.g001
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Fig 2A–2D). Those with low Modified Rio Scores, and without relapses in year 0–1, appeared
to have lower risk of disability progression in the first two years, but this effect disappeared
with longer follow-up (Fig 2A and 2B).
Modified Rio Score predicts short-term but not medium-term disability
progression
A limitation of Kaplan-Meier curves is that events (in this case disability progression) are
treated as irreversible, which is inappropriate given that EDSS can improve with treatment. In
addition, it was observed that curves converge and cross in both the Modified Rio Score and
relapses survival analyses (Fig 2A and 2B), suggesting that any association between inflamma-
tory biomarkers and disability progression may change over time. Therefore, contingency
tables were used to investigate the relationship between inflammatory biomarkers and EDSS
progression at specific time points of years 1, 2, 3, and 3–7.
Modified Rio Score in the first year of treatment predicted EDSS progression at year 1 and
2 (Year 1: 15/111 vs 9/34 vs 5/16 EDSS progression for those with Mod Rio Score of 0, 1, 2
respectively. Mod Rio Score 1, Odds Ratio (OR) 2.3, 95% Confidence Interval (CI) 0.9–5.9;
Mod Rio Score 2, OR 2.9, CI 0.9–9.6; p<0.05. Year 2: 25/111 vs 12/34 vs 7/16 EDSS progres-
sion for those with Mod Rio Score of 0, 1, 2 respectively. Mod Rio Score 1, OR 1.9, CI 0.8–4.3;
Mod Rio Score 2, OR 2.7, CI 0.9–7.9; p<0.05; Fig 3A and 3B). However, it did not predict
EDSS progression at year 3, or year 3–7 (Year 3: 35/111 vs 12/34 vs 6/16 EDSS progression for
those with Mod Rio Score of 0, 1, 2 respectively. Mod Rio Score 1, OR 1.2, CI 0.4–2.7; Mod Rio
Score 2, OR 1.3, CI 0.4–3.9; p = 0.57; Year 3–7: 45/111 vs 12/34 vs 3/16 EDSS progression for
those with Mod Rio Score of 0, 1, 2 respectively. Mod Rio Score 1, OR 0.8, CI 0.4–1.8; Mod Rio
Score 2, OR 0.3, CI 0.1–1.3; p = 0.11; Fig 3C and 3D). If anything, there was a paradoxical trend
towards lower Modified Rio Score predicting EDSS progression in years 3–7, although this was
not statistically significant (Fig 3D). This shift over time in the polarity of the predictive value of
Table 2. Characteristics of study cohort, presented as mean ± SD. Percentages are rounded to the nearest integer, and may not add to 100%.
Full Cohort Year 3–7 EDSS Progression Responders Year 3–7 EDSS Progression Non-Responders
Sample Number 161 101 60
Mean Age (Years) 40.6 ± 10.2 39.7 ± 10.8 42.1 ± 9.1
Sex
Female 101 (63%) 67 (66%) 34 (57%)
Male 60 (37%) 34 (34%) 26 (43%)
Disease Duration (years) 8.9 ± 6.1 8.7 ± 6.0 9.4 ± 6.2
Number of previous treatments
0 42 (26%) 30 (30%) 12 (20%)
1 89 (55%) 52 (51%) 37 (62%)
2 21 (13%) 14 (14%) 7 (12%)
3 8 (5%) 4 (4%) 4 (7%)
4 1 (1%) 1 (1%) 0
Relapses 2 years prior to natalizumab 3.0 ± 1.3 3.0 ± 1.3 2.9 ± 1.2
Pre natalizumab EDSS 4.2 ± 1.8 4.1 ± 1.9 4.4 ± 1.6
Most recent EDSS 4.5 ± 2.0 3.7 ± 2.0 5.8 ± 1.4 ****
Years of follow-up after natalizumab 4.3 ± 0.8 4.3 ± 0.8 4.3 ± 0.9
When divided into Year 3–7 EDSS Progression Responders and Non-Responders, there were no significant differences between characteristics, other than
‘most recent EDSS’ (**** = p<0.0001).
doi:10.1371/journal.pone.0169546.t002
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Modified Rio Score on disability was caused by year-on-year increases in the proportion of non-
responders within the Mod Rio Score 0 group (p<0.0001), versus no significant year-on-year
change in the proportion of non-responders within the Mod Rio Score 1–2 group (p = 0.90).
Relapses and MRI activity predict short-term but not medium-term
disability progression
Similar trends were observed when studying on-treatment relapses and MRI activity in isola-
tion. Relapses in the first year of treatment predicted EDSS progression at year 1 and 2 (Year 1:
16/115 vs 13/48 EDSS progression for those without and with relapses respectively. OR 2.4, CI
1.1–5.6, p<0.05. Year 2: 26/115 vs 18/48 EDSS progression for those without and with relapses
respectively. OR 2.2, CI 1.1–4.6, p<0.05; Fig 3E and 3F). However, they did not predict EDSS
progression at year 3, or years 3–7 (Year 3: 36/115 vs 17/48 EDSS progression for those without
and with relapses respectively. OR 1.3, CI 0.6–2.6, p = 0.58. Year 3–7: 46/115 vs 14/48 EDSS
progression for those without and with relapses respectively. OR 0.7, CI 0.3–1.4, p = 0.28; Fig
3G and 3H). If anything, there was a paradoxical trend towards lack of relapses predicting
EDSS progression at years 3–7, although this was not statistically significant (Fig 3H). New
MRI activity in the first year of treatment did not predict EDSS progression at any future time
Fig 2. On-treatment inflammatory disease activity does not affect overall disability survival analysis. First year after natalizumab
initiation Modified Rio Score (A), relapses (B), and MRI activity (C), and second year after natalizumab initiation relapses (D), versus survival
from EDSS progression over time. Black markers on survival lines represent the duration of follow-up data for those participants who have
not undergone EDSS progression (i.e. the time of subject censorship in survival analysis).
doi:10.1371/journal.pone.0169546.g002
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point (Year 1: 25/113 vs 4/28 EDSS progression for those without and with new MRI activity
respectively. OR 0.7, CI 0.2–2.3, p = 0.78 Year 2: 37/113 vs 7/28 EDSS progression for those
without and with new MRI activity respectively. OR 0.86, CI 0.3–2.2, p = 0.82. Year 3: 46/113
vs 7/28 EDSS progression for those without and with new MRI activity respectively. OR 0.6, CI
0.2–1.6, p = 0.38. Year 3–7: 54/113 vs 6/28 EDSS progression for those without and with new
MRI activity respectively. OR 0.4, CI 0.2–1.0, p = 0.08; Fig 3I–3L). Again, there was a paradoxi-
cal trend towards lack of new MRI activity predicting EDSS progression at years 3–7, although
this was not statistically significant (Fig 3L). As before, this shift over time in the polarity of the
predictive value of relapses and MRI activity on disability was caused by year-on-year increases
in the proportion of non-responders within the ‘no relapses group’ (p<0.0001) and ‘no new
MRI activity group’ (p<0.0001), versus no significant year-on-year change in the proportion
of non-responders within the ‘relapses group’ (p = 0.89) and the ‘new MRI activity group’
(p = 0.54).
Similarly, the subgroup of patients with new gadolinium-enhancing MRI lesions in the first
year of treatment (n = 14) had no difference in EDSS progression in future years (Year 1: 25/
147 vs 4/14 EDSS progression for those without and with new gadolinium enhancing lesions
respectively. OR 2.0, CI 0.6–6.7, p = 0.28. Year 2: 40/147 vs 4/14 EDSS progression for those
without and with new gadolinium enhancing lesions respectively. OR 1.1, CI 0.3–3.6, p = 1.0.
Year 3: 48/147 vs 4/14 EDSS progression for those without and with new gadolinium enhanc-
ing lesions respectively. OR 0.8, CI 0.2–2.8, p = 1.0.Year 3–7: 56/147 vs 4/14 EDSS progression
for those without and with new gadolinium enhancing lesions respectively. OR 0.65, CI 0.2–
2.2, p = 0.57). Relapses in the second year of treatment were also unable to predict EDSS prog-
ress at future time points (Year 1: 17/109 vs 12/52 EDSS progression for those without and
with relapses respectively. OR 1.6, CI 0.7–3.7, p = 0.28. Year 2: 28/109 vs 16/52 EDSS progres-
sion for those without and with relapses respectively. OR 1.3, CI 0.6–2.7, p = 0.57. Year 3: 34/
109 vs 19/52 EDSS progression for those without and with relapses respectively. OR 1.3, CI
0.6–2.5, p = 0.59. Year 3–7: 40/109 vs 20/52 EDSS progression for those without and with
relapses respectively. OR 1.1, CI 0.5–2.1, p = 0.86; Fig 3M–3P).
Results are not affected by change in medication, baseline disability, or
neutralising antibodies
As may be expected, patients with inflammatory activity on natalizumab treatment were more
likely to switch to other disease modifying drugs, such as alemtuzumab, fingolimod, or cyclo-
phosphamide. For example, 8/46 of those with relapses in year 0–1 switched to an alternative
treatment at some point during the 3–7 year follow-up period of this study, versus 1/115 of
those with no relapses. However, the trends observed in this study remained consistent with
subgroup analyses after exclusion of those that switched to other medications (for example as
represented in Fig 4). Trends also remained consistent with subgroup analysis restricted to
those with baseline EDSS scores <4 (n = 68) or4 (n = 93), and also after exclusion of those
with neutralising antibodies (n = 6). There was no significant difference in mean follow-up
time between those with different Modified Rio Scores, or indeed any of the other individual
inflammatory measures.
Logistic regression multivariable model considered variables relating to demographics,
disease history, and markers of inflammatory disease (age at natalizumab initiation, sex,
Fig 3. On-treatment inflammatory disease activity predicts short-term but not long-term disability outcomes. Early measures of on-
treatment inflammatory disease in first year (A-L) and second year (M-P) after treatment initiation, versus percentage of future EDSS
Progression in year 1 (A, E, I, M), year 2 (B, F, J, N), year 3 (C, G, K, O), and years 3–7 (D, H, L, P). * denotes p<0.05.
doi:10.1371/journal.pone.0169546.g003
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pre-natalizumab relapse rate, pre-natalizumab MRI lesion count, pre-natalizumab MRI
enhancing lesion count, number of previous treatments, post-natalizumab relapse rate, and
post-natalizumab new MRI lesions), and found no further predictive relationships for disabil-
ity outcomes (multiple r-squared: 0.051, p = 0.46).
Relapses in the first year of treatment with natalizumab predict further
relapses
Relapses in year 0–1 of treatment were correlated with the risk of further relapses in years 1–3.
35 of 115 (30%) with no relapses in year 0–1 reported relapses in years 1–3. In contrast, 31 out
of 46 (67%) with relapses in year 0–1 reported relapses in years 1–3 (OR 4.7, CI 2.3–9.8,
p<0.0001).
Discussion
This is the first study to report on-treatment predictive measures of long term disability out-
comes in a cohort of patients on natalizumab. We find that relapses and Modified Rio Score in
the first year of natalizumab treatment predict year 1 and year 2 EDSS progression. However,
this effect disappears after three years of follow-up. If anything, there is a consistent paradoxi-
cal trend towards on-treatment relapses, MRI activity, and high Modified Rio Score predicting
better 3–7 year disability outcomes, versus pre-treatment baseline EDSS, although this did not
reach statistical significance. This shift over time was driven by highly significant year-on-year
increases in disability progression specifically in those without on-treatment inflammatory
activity. In this group it was less likely for the EDSS to worsen in the first 1–2 years, but far
more likely for the EDSS to worsen over each subsequent year. Results were consistent when
restricted to those who remained on natalizumab throughout the follow-up period. Given this,
our data suggests a disconnect between natalizumab’s ability to suppress focal inflammatory
activity underlying relapses and new T2 MRI lesions, and its putative effect on the progression
of long-term disability.
Previous studies looking at predictive measures of treatment response have tended to focus
on earlier generation MS treatments, namely interferons and glatiramer acetate. Like ours,
these studies identified on-treatment MRI activity and relapses as medium-term (3 years)
prognostic markers of EDSS progression and/or further relapses.[5–11] However, the majority
had limited follow up and thus conclusions on long term disability could not be made.[6–11]
Fig 4. Results remain consistent after exclusion of those that switched to other treatment. After exclusion of patients who switched
from natalizumab to other disease modifying treatment. On-treatment relapses in first year after treatment initiation versus percentage of
future EDSS Progression in year 1 (A), year 2 (B), year 3 (C), and years 3–7 (D).
doi:10.1371/journal.pone.0169546.g004
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It is possible that the predictive effect of relapses and MRI activity on short-term EDSS out-
comes could reflect a predictive effect partly on relapse-mediated worsening of disability,
rather than true progressive neurodegeneration. Related to this is a potential reporting bias,
especially in studies based in the working neurology clinic, where it can be challenging to dis-
tinguish relapses from a true worsening of EDSS, and so both may be reported interdepen-
dently. This reporting bias decreases with long-term follow-up. In addition, we found that
relapses in year 0–1 predict further relapses in years 1–3, in common with several of the above
studies.[6, 7, 9, 11] Again, a patient reporting bias is likely to contribute to this association, and
long-term disability progression should remain the preferred primary outcome. It would be of
interest whether long-term follow-up data from the above studies would find results consistent
with ours. Equally, it could be that the prognostic importance of relapses and MRI activity dif-
fers between interferon, glatiramer acetate, and natalizumab treatment.
Year 0–1 on-treatment MRI activity did not predict poor disability outcomes at any time
point. This expands upon a previous post hoc analysis of randomized controlled trial data
showing the clinical efficacy of natalizumab on year 0–2 relapses even in those with on-treat-
ment MRI activity.[17] Of course, some new T2 lesions might have developed before natalizu-
mab became effective, and future datasets should aim to “re-baseline” the patients with MRI
scans performed 6 months after natalizumab initiation.[18] However, since gadolinium
enhancing MRI also did not predict poor disability outcomes in our study, this suggests the
lack of correlation between new MRI activity and long-term prognosis is real. Similarly, some
relapses in years 0–1 may have developed before natalizumab became effective, but the data on
year 1–2 relapses corroborates the finding of lack of predictive value of relapses on long-term
disability.
Several caveats exist in this study, and must be considered. The cohort size is modest, and
results should be replicated in larger cohorts. Our cohort had a high baseline EDSS (mean
baseline EDSS 4.2) in comparison to interferon and glatiramer acetate studies (mean baseline
EDSS 2 to 3), reflecting the fact that at the time of data collection, there were limited treatment
options available for highly active relapsing-remitting and relapsing-progressive MS. Our
cohort had poorer outcomes—46 of 161 patients had a relapse in the first year and 44/161 had
EDSS progression by year 2—than previously described natalizumab cohorts with less baseline
disability such as those in the pivotal randomised controlled trials.[13,14] Although some
patients gained clear benefit from treatment it is likely that some patients within our cohort
had a progressive component to their disease which was not responsive to treatment.[19, 20]
Within this cohort, it could be that on-treatment breakthrough inflammatory activity is not a
poor prognostic marker for long-term disability since it signifies that the patient does have an
ongoing treatable focal inflammatory disease component, as opposed to others in the cohort
who may have entered a predominantly irreversible neurodegenerative progressive stage of
disease. That said, those with on-treatment inflammatory activity had equivalent baseline age
and EDSS to those without on-treatment inflammatory activity in our cohort. In addition,
results remained consistent when restricted to those with baseline EDSS <4. Another caveat
arises in that follow-up time was variable, although always greater than 3 years. Kaplan-Meier
curves tended to converge after this 3-year time point, bringing about the possibility that asso-
ciations were affected by selection bias related to duration of follow-up, although this seems
unlikely since follow-up duration was consistent between groups.
The observational nature of this study means we cannot speculate whether patients might
have gained greater benefit from other treatments. Randomised controlled interventional
studies are required to investigate whether those with breakthrough inflammatory activity
would benefit from switching to other highly active treatments. Nevertheless, the data from
this study argues that neither decrease in relapse rate, MRI activity, nor short-term stability of
Inflammatory Activity and Disability Outcomes after Natalizumab
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EDSS can be assumed to equate to better long-term prognosis. This has far-reaching implica-
tions, from the treating physician assessing those with on-treatment clinical activity, to the
design and interpretation of the clinical trial.
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